Continuing Pharmacy Education / CE Master List / Information overload in Chronic Coronary Disease – RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Information overload in Chronic Coronary Disease – RECORDED WEBINAR

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's symposium had an overall topic of Information Overload.

Learning Objectives

  • Determine if a patient has chronic cardiac disease (CCD).
  • Identify lifestyle modifications that can reduce the risk of CCD.
  • Identify therapies that can reduce final health outcomes for specific CCD patient types to design successful drug regimens.
  • Describe how the steps in the PPCP process can be applied when reviewing a cardiac patient.

Activity Release Dates

Released:  April 24, 2025
Expires:  April 24, 2028

Course Fee

$17 Pharmacist

ACPE UAN Codes

 0009-0000-25-028-H01-P

Session Code

25RS28-TXJ88

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-25-028-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

C. Michael White, PharmD, FCCP, FCP
BOT Distinguished Professor and Chair of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, CT

    

Faculty Disclosure

  • Dr. White doesn't have any relationships with ineligible companies.

 

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test Pharmacist

1. A female patient is interested in lifestyle modification. Which of the following would you recommend?
a. Switch from EVOO to coconut oil
b. Switch from smoking weed to “doing” crystal methamphetamine
c. Limit alcohol to a maximum of 1 drink a day

2. A patient with CCD is determined to have “high risk” of experiencing an ASCVD event. The patient cannot receive high- or even moderate-intensity statins due to a history of significant rises in liver enzymes 8-10 weeks after initiation on two occasions. Which is true of the patient’s recommended lipid regimen?
a. The patient needs high-intensity statin regardless of the liver issues and ezetimibe should be added if the LDL on the statin is over 70mg/dL
b. The patient could receive a low intensity statin + a PCSK9 inhibitor and if the LDL remains over 70mg/dL, ezetimibe can be added
c. The patient could receive a PCSK9 inhibitor and if the LDL remains over 70mg/dL, ezetimibe can be added

3. Why can’t metoprolol tartrate be used to terminate a new onset angina pectoris event?
a. Because the onset of action is 30 minutes, and the maximum effect is felt 2 hours after ingestion
b. Because I am a pharmacist and I said so, that’s why
c. Because metoprolol does not work on the coronary arteries and only coronary dilators can be used for acute angina pectoris events

4. A student is explaining the PPCP process to you. Which of the following statements would you question and ask the student to research?
a. The PPCP process helps structure an assessment to be sure that important drug related problems are all included
b. Major pharmacy organizations agreed upon this process to show regulators, clinicians, patients, payers and insurers our unique patient services
c. “PPCP” is an old term; major professional organizations have replaced it with the subjective-objective-assessment-plan process

5. When would it be useful to recommend nitroglycerin spray instead of sublingual nitroglycerin?
a. In a patient taking an anticholinergic
b. In a patient taking an SSRI
c. In a patient taking benzodiazepines

6. JP is a patient who has rheumatoid arthritis and chronic coronary disease. He has an hsCRP test taken and the level is 7.2 mg/dL. Would this patient be a candidate for colchicine therapy according to the AHA/ACC Guideline and why or why not?
a. Yes, colchicine should be used in all people with elevated hsCRP
b. Yes, colchicine should be used in all patients regardless of hsCRP
c. No, specific disease modifying antirheumatic drug are used in patients with RA

7. AT is a patient with heart failure with reduced ejection fraction, who also has chronic coronary disease. Would an SGLT2 inhibitor or a GLP-1 agonist be preferred for the treatment of this patient?
a. Neither drug should be used at all
b. The SGLT-2 inhibitor would be preferred
c. The GLP-1 agonist would be preferred

8. WC is a patient who just had a PCI procedure but also has atrial fibrillation and is treated with rivaroxaban. What is the proper regimen to prevent stent occlusion?
a. Clopidogrel + aspirin + rivaroxaban for one month, then clopidogrel + rivaroxaban for 5 months, then just rivaroxaban alone thereafter
b. Clopidogrel + aspirin + rivaroxaban for six months, then clopidogrel + rivaroxaban for 6 months, then just rivaroxaban alone thereafter
c. Clopidogrel + aspirin + rivaroxaban for 12 months, then rivaroxaban + clopidogrel then rivaroxaban for 6 months, then rivaroxaban alone